Category Archives: Human Robots
#436774 AI Is an Energy-Guzzler. We Need to ...
There is a saying that has emerged among the tech set in recent years: AI is the new electricity. The platitude refers to the disruptive power of artificial intelligence for driving advances in everything from transportation to predicting the weather.
Of course, the computers and data centers that support AI’s complex algorithms are very much dependent on electricity. While that may seem pretty obvious, it may be surprising to learn that AI can be extremely power-hungry, especially when it comes to training the models that enable machines to recognize your face in a photo or for Alexa to understand a voice command.
The scale of the problem is difficult to measure, but there have been some attempts to put hard numbers on the environmental cost.
For instance, one paper published on the open-access repository arXiv claimed that the carbon emissions for training a basic natural language processing (NLP) model—algorithms that process and understand language-based data—are equal to the CO2 produced by the average American lifestyle over two years. A more robust model required the equivalent of about 17 years’ worth of emissions.
The authors noted that about a decade ago, NLP models could do the job on a regular commercial laptop. Today, much more sophisticated AI models use specialized hardware like graphics processing units, or GPUs, a chip technology popularized by Nvidia for gaming that also proved capable of supporting computing tasks for AI.
OpenAI, a nonprofit research organization co-founded by tech prophet and profiteer Elon Musk, said that the computing power “used in the largest AI training runs has been increasing exponentially with a 3.4-month doubling time” since 2012. That’s about the time that GPUs started making their way into AI computing systems.
Getting Smarter About AI Chip Design
While GPUs from Nvidia remain the gold standard in AI hardware today, a number of startups have emerged to challenge the company’s industry dominance. Many are building chipsets designed to work more like the human brain, an area that’s been dubbed neuromorphic computing.
One of the leading companies in this arena is Graphcore, a UK startup that has raised more than $450 million and boasts a valuation of $1.95 billion. The company’s version of the GPU is an IPU, which stands for intelligence processing unit.
To build a computer brain more akin to a human one, the big brains at Graphcore are bypassing the precise but time-consuming number-crunching typical of a conventional microprocessor with one that’s content to get by on less precise arithmetic.
The results are essentially the same, but IPUs get the job done much quicker. Graphcore claimed it was able to train the popular BERT NLP model in just 56 hours, while tripling throughput and reducing latency by 20 percent.
An article in Bloomberg compared the approach to the “human brain shifting from calculating the exact GPS coordinates of a restaurant to just remembering its name and neighborhood.”
Graphcore’s hardware architecture also features more built-in memory processing, boosting efficiency because there’s less need to send as much data back and forth between chips. That’s similar to an approach adopted by a team of researchers in Italy that recently published a paper about a new computing circuit.
The novel circuit uses a device called a memristor that can execute a mathematical function known as a regression in just one operation. The approach attempts to mimic the human brain by processing data directly within the memory.
Daniele Ielmini at Politecnico di Milano, co-author of the Science Advances paper, told Singularity Hub that the main advantage of in-memory computing is the lack of any data movement, which is the main bottleneck of conventional digital computers, as well as the parallel processing of data that enables the intimate interactions among various currents and voltages within the memory array.
Ielmini explained that in-memory computing can have a “tremendous impact on energy efficiency of AI, as it can accelerate very advanced tasks by physical computation within the memory circuit.” He added that such “radical ideas” in hardware design will be needed in order to make a quantum leap in energy efficiency and time.
It’s Not Just a Hardware Problem
The emphasis on designing more efficient chip architecture might suggest that AI’s power hunger is essentially a hardware problem. That’s not the case, Ielmini noted.
“We believe that significant progress could be made by similar breakthroughs at the algorithm and dataset levels,” he said.
He’s not the only one.
One of the key research areas at Qualcomm’s AI research lab is energy efficiency. Max Welling, vice president of Qualcomm Technology R&D division, has written about the need for more power-efficient algorithms. He has gone so far as to suggest that AI algorithms will be measured by the amount of intelligence they provide per joule.
One emerging area being studied, Welling wrote, is the use of Bayesian deep learning for deep neural networks.
It’s all pretty heady stuff and easily the subject of a PhD thesis. The main thing to understand in this context is that Bayesian deep learning is another attempt to mimic how the brain processes information by introducing random values into the neural network. A benefit of Bayesian deep learning is that it compresses and quantifies data in order to reduce the complexity of a neural network. In turn, that reduces the number of “steps” required to recognize a dog as a dog—and the energy required to get the right result.
A team at Oak Ridge National Laboratory has previously demonstrated another way to improve AI energy efficiency by converting deep learning neural networks into what’s called a spiking neural network. The researchers spiked their deep spiking neural network (DSNN) by introducing a stochastic process that adds random values like Bayesian deep learning.
The DSNN actually imitates the way neurons interact with synapses, which send signals between brain cells. Individual “spikes” in the network indicate where to perform computations, lowering energy consumption because it disregards unnecessary computations.
The system is being used by cancer researchers to scan millions of clinical reports to unearth insights on causes and treatments of the disease.
Helping battle cancer is only one of many rewards we may reap from artificial intelligence in the future, as long as the benefits of those algorithms outweigh the costs of using them.
“Making AI more energy-efficient is an overarching objective that spans the fields of algorithms, systems, architecture, circuits, and devices,” Ielmini said.
Image Credit: analogicus from Pixabay Continue reading
Posted in Human Robots
#436013 Know your Robot from your Humanoid, ...
This video addresses the difference between a robot, droid, cyborg, humanoid, and an android.
Posted in Human Robots
#436578 AI Just Discovered a New Antibiotic to ...
Penicillin, one of the greatest discoveries in the history of medicine, was a product of chance.
After returning from summer vacation in September 1928, bacteriologist Alexander Fleming found a colony of bacteria he’d left in his London lab had sprouted a fungus. Curiously, wherever the bacteria contacted the fungus, their cell walls broke down and they died. Fleming guessed the fungus was secreting something lethal to the bacteria—and the rest is history.
Fleming’s discovery of penicillin and its later isolation, synthesis, and scaling in the 1940s released a flood of antibiotic discoveries in the next few decades. Bacteria and fungi had been waging an ancient war against each other, and the weapons they’d evolved over eons turned out to be humanity’s best defense against bacterial infection and disease.
In recent decades, however, the flood of new antibiotics has slowed to a trickle.
Their development is uneconomical for drug companies, and the low-hanging fruit has long been picked. We’re now facing the emergence of strains of super bacteria resistant to one or more antibiotics and an aging arsenal to fight them with. Gone unchallenged, an estimated 700,000 deaths worldwide due to drug resistance could rise to as many as 10 million in 2050.
Increasingly, scientists warn the tide is turning, and we need a new strategy to keep pace with the remarkably quick and boundlessly creative tactics of bacterial evolution.
But where the golden age of antibiotics was sparked by serendipity, human intelligence, and natural molecular weapons, its sequel may lean on the uncanny eye of artificial intelligence to screen millions of compounds—and even design new ones—in search of the next penicillin.
Hal Discovers a Powerful Antibiotic
In a paper published this week in the journal, Cell, MIT researchers took a step in this direction. The team says their machine learning algorithm discovered a powerful new antibiotic.
Named for the AI in 2001: A Space Odyssey, the antibiotic, halicin, successfully wiped out dozens of bacterial strains, including some of the most dangerous drug-resistant bacteria on the World Health Organization’s most wanted list. The bacteria also failed to develop resistance to E. coli during a month of observation, in stark contrast to existing antibiotic ciprofloxacin.
“In terms of antibiotic discovery, this is absolutely a first,” Regina Barzilay, a senior author on the study and computer science professor at MIT, told The Guardian.
The algorithm that discovered halicin was trained on the molecular features of 2,500 compounds. Nearly half were FDA-approved drugs, and another 800 naturally occurring. The researchers specifically tuned the algorithm to look for molecules with antibiotic properties but whose structures would differ from existing antibiotics (as halicin’s does). Using another machine learning program, they screened the results for those likely to be safe for humans.
Early study suggests halicin attacks the bacteria’s cell membranes, disrupting their ability to produce energy. Protecting the cell membrane from halicin might take more than one or two genetic mutations, which could account for its impressive ability to prevent resistance.
“I think this is one of the more powerful antibiotics that has been discovered to date,” James Collins, an MIT professor of bioengineering and senior author told The Guardian. “It has remarkable activity against a broad range of antibiotic-resistant pathogens.”
Beyond tests in petri-dish bacterial colonies, the team also tested halicin in mice. The antibiotic cleared up infections of a strain of bacteria resistant to all known antibiotics in a day. The team plans further study in partnership with a pharmaceutical company or nonprofit, and they hope to eventually prove it safe and effective for use in humans.
This last bit remains the trickiest step, given the cost of getting a new drug approved. But Collins hopes algorithms like theirs will help. “We could dramatically reduce the cost required to get through clinical trials,” he told the Financial Times.
A Universe of Drugs Awaits
The bigger story may be what happens next.
How many novel antibiotics await discovery, and how far can AI screening take us? The initial 6,000 compounds scanned by Barzilay and Collins’s team is a drop in the bucket.
They’ve already begun digging deeper by setting the algorithm loose on 100 million molecules from an online library of 1.5 billion compounds called the ZINC15 database. This first search took three days and turned up 23 more candidates that, like halicin, differ structurally from existing antibiotics and may be safe for humans. Two of these—which the team will study further—appear to be especially powerful.
Even more ambitiously, Barzilay hopes the approach can find or even design novel antibiotics that kill bad bacteria with alacrity while sparing the good guys. In this way, a round of antibiotics would cure whatever ails you without taking out your whole gut microbiome in the process.
All this is part of a larger movement to use machine learning algorithms in the long, expensive process of drug discovery. Other players in the area are also training AI on the vast possibility space of drug-like compounds. Last fall, one of the leaders in the area, Insilico, was challenged by a partner to see just how fast their method could do the job. The company turned out a new a proof-of-concept drug candidate in only 46 days.
The field is still developing, however, and it has yet to be seen exactly how valuable these approaches will be in practice. Barzilay is optimistic though.
“There is still a question of whether machine-learning tools are really doing something intelligent in healthcare, and how we can develop them to be workhorses in the pharmaceuticals industry,” she said. “This shows how far you can adapt this tool.”
Image Credit: Halicin (top row) prevented the development of antibiotic resistance in E. coli, while ciprofloxacin (bottom row) did not. Collins Lab at MIT Continue reading
Posted in Human Robots